Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ANIX |
---|---|---|
09:32 ET | 5636 | 2.5 |
09:54 ET | 122 | 2.465 |
10:14 ET | 583 | 2.48 |
10:21 ET | 300 | 2.46 |
10:50 ET | 100 | 2.48 |
10:51 ET | 8100 | 2.465 |
10:57 ET | 100 | 2.47 |
11:13 ET | 100 | 2.478 |
11:26 ET | 602 | 2.48 |
11:49 ET | 1108 | 2.485 |
11:58 ET | 4632 | 2.49 |
12:14 ET | 200 | 2.49 |
12:20 ET | 1792 | 2.46 |
12:34 ET | 120 | 2.465 |
12:38 ET | 1196 | 2.4501 |
12:48 ET | 100 | 2.45 |
12:57 ET | 1200 | 2.45 |
12:59 ET | 1200 | 2.45 |
01:14 ET | 200 | 2.465 |
01:15 ET | 400 | 2.4648 |
01:21 ET | 200 | 2.45 |
01:26 ET | 415 | 2.45 |
01:30 ET | 100 | 2.47 |
01:32 ET | 2000 | 2.46 |
01:42 ET | 115 | 2.455 |
02:00 ET | 100 | 2.4449 |
02:11 ET | 100 | 2.4406 |
02:20 ET | 350 | 2.46 |
02:27 ET | 1606 | 2.4548 |
02:38 ET | 200 | 2.4578 |
03:20 ET | 200 | 2.47 |
03:30 ET | 100 | 2.46 |
03:43 ET | 417 | 2.465 |
03:48 ET | 100 | 2.465 |
03:50 ET | 100 | 2.47 |
03:59 ET | 1265 | 2.48 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Anixa Biosciences Inc | 79.1M | -7.2x | --- |
Benitec Biopharma Inc | 80.1M | -0.8x | --- |
Sellas Life Sciences Group Inc | 79.7M | -1.2x | --- |
Serina Therapeutics Inc | 80.7M | -0.7x | --- |
Entera Bio Ltd | 80.5M | -8.5x | --- |
Provectus Biopharmaceuticals Inc | 79.7M | -27.2x | --- |
Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies that are focused on critical unmet needs in oncology. Its segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Other. Its vaccine programs include the development of a preventative vaccine against triple negative breast cancer (TNBC), the most lethal form of breast cancer, as well as other forms of breast cancer and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T cell therapy, a novel form of chimeric antigen receptor T cell (CAR-T) technology, initially focused on treating ovarian cancer, which is being developed by its subsidiary, Certainty Therapeutics, Inc. (Certainty). Certainty is developing immuno-therapy drugs against cancer. The Company’s vaccine portfolio consists of technology focused on the immunization against specific retired proteins.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $79.1M |
---|---|
Revenue (TTM) | $210.0K |
Shares Outstanding | 31.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.84 |
EPS | $-0.35 |
Book Value | $0.78 |
P/E Ratio | -7.2x |
Price/Sales (TTM) | 376.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -5,744.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.